Molecular Partners AG (OTCMKTS:MLLCF – Get Rating) was the recipient of a significant decline in short interest in November. As of November 30th, there was short interest totalling 162,100 shares, a decline of 12.5% from the November 15th total of 185,300 shares. Based on an average daily volume of 100 shares, the short-interest ratio is presently 1,621.0 days.
Molecular Partners Stock Performance
Shares of MLLCF stock opened at $6.25 on Friday. The firm has a fifty day moving average price of $6.39 and a 200 day moving average price of $6.22. Molecular Partners has a 12 month low of $5.16 and a 12 month high of $32.00.
Get
Molecular Partners alerts:
About Molecular Partners
(Get Rating)
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus.
Recommended Stories
- Get a free copy of the StockNews.com research report on Molecular Partners (MLLCF)
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
Molecular Partners AG (OTCMKTS:MLLCF – Get Rating) was the recipient of a significant decline in short interest in November. As of November 30th, there was short interest totalling 162,100 shares, a decline of 12.5% from the November 15th total of 185,300 shares. Based on an average daily volume of 100 shares, the short-interest ratio is presently 1,621.0 days.
分子合作夥伴股份公司(場外交易代碼：MLLCF-GET Rating)是11月份空頭股數價格大幅下降的接受者。截至11月30日，空頭股數共有162,100股，較11月15日的185,300股下跌12.5%。以日均成交量100股計算，目前短息比率為1,621.0天。
Molecular Partners Stock Performance
Shares of MLLCF stock opened at $6.25 on Friday. The firm has a fifty day moving average price of $6.39 and a 200 day moving average price of $6.22. Molecular Partners has a 12 month low of $5.16 and a 12 month high of $32.00.
MLLCF股票週五開盤報6.25美元。該公司的50日移動平均價為6.39美元，200日移動平均價為6.22美元。Molecal Partners的12個月低點為5.16美元，12個月高位為32.00美元。
Get
Molecular Partners
alerts:
About Molecular Partners
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus.
分子夥伴公司是一家臨床階段的生物製藥公司，專注於治療性蛋白質的發現、開發和商業化。它的候選產品包括用於治療新血管濕性老年性黃斑變性和糖尿病黃斑水腫的候選DARPin藥物Abempar，該藥物處於第三階段臨床試驗；以及針對SARS-CoV-2病毒的多特異性DARPin候選藥物MP0420。
Recommended Stories
- Get a free copy of the StockNews.com research report on Molecular Partners (MLLCF)
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
- 免費獲取StockNews.com關於分子夥伴的研究報告(MLLCF)
- MarketBeat：回顧一週12/12-12/16
- 哪兩家藍籌科技公司提高了他們的指引？
- 你應該擔心埃隆·馬斯克出售他持有的特斯拉股票嗎？
- 拖拉機庫存能否突破杯柄收購點？
- 現在不是購買Lennar的時候，但時機即將到來
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
每日收到分子合作夥伴的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收分子合作夥伴和相關公司的最新新聞和分析師評級的每日摘要。
